Showing 981-990 of 1635 results for "".
- IrisVision Names Naeem Kayani President & Chief Operating Officerhttps://modernod.com/news/irisvision-names-naeem-kayani-president-chief-operating-officer/2479431/IrisVision announced the addition of Naeem Kayani to serve as President and Chief Operating Officer. Launched in 2017, IrisVision’s flagship consumer product employs breakthrough, smart software lens technology that leverages functional areas of the eyes to restore vision instantly. Design
- United Nations Resolution Designed to Tackle Preventable Sight Losshttps://modernod.com/news/united-nations-resolution-designed-to-tackle-preventable-sight-loss/2479406/The United Nations General Assembly (UNGA) has adopted
- Nanoscope Therapeutics Announces First Patient Dosed in Phase 2b Trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with RPhttps://modernod.com/news/nanoscope-therapeutics-announces-first-patient-dosed-in-phase-2b-trial-of-optogenetic-gene-monotherapy-to-restore-vision-in-patients-with-rp/2479381/Nanoscope Therapeutics announced that the first patient had been dosed in its phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with retinitis pigme
- Belkin Laser Announces Corporate Name Change to Belkin Visionhttps://modernod.com/news/belkin-laser-announces-corporate-name-change-to-belkin-vision/2479352/Israel-based medical device company Belkin Laser announced that it will begin operating under the new name of Belkin Vision. The name change is a strategic decision that will better reflect the company’s capability to solve future ophthalmic challenges, according to a company stateme
- William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directorshttps://modernod.com/news/william-j-link-phd-named-chairman-of-allegro-ophthalmics-board-of-directors/2479313/Allegro Ophthalmics announced that William J. Link, PhD, has been appointed chairman by the company’s board of directors and that Stephanie Yee was named vice president of finance. “I am thrilled that Bill has agreed to serve as our board chairman and pleased to promote Stephanie as VP of
- Arnaud Lacoste Is Named Chief Scientific Officer of Aurion Biotechhttps://modernod.com/news/arnaud-lacoste-is-named-chief-scientific-officer-of-aurion-biotech/2479293/Arnaud Lacoste, MBA, PhD, has been named chief scientific officer of Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies. Arnaud will lead R&D teams based in Boston and Seattle. “Arnaud is a brilliant scientist, a strategic e
- Lighthouse Guild Announces the Naming of The Dorothy Strelsin Behavioral Health Clinichttps://modernod.com/news/lighthouse-guild-announces-the-naming-of-the-dorothy-strelsin-behavioral-health-clinic/2479278/In recognition of a long-time supporter of Lighthouse Guild, the organization has announced the naming of The Dorothy Strelsin Behavioral Health Clinic. Lighthouse Guild is very grateful for the steadfast support of Dorothy Strelsin, who in her lifetime made numerous initiatives possible, includi
- Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosahttps://modernod.com/news/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision-in-11-patients-blinded-by-retinitis-pigmentosa/2479261/Nanoscope Therapeutics announced that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through 1 year following a single intravitreal injection in a phase 1/2a clinical study with MCO. “We expect to begin the first randomized, placebo-contro
- GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of Lumevoq Versus Natural Historyhttps://modernod.com/news/gensight-biologics-announces-publication-of-indirect-comparison-showing-treatment-effect-of-lumevoq-versus-natural-history/2479249/GenSight Biologics announced that the journal Frontiers in Neurology has published results of the indirect comparison of the evolution of visual outcomes in patients treated with Lumevoq gene therapy with the spontaneous evolution in natural history (NH) studies of Leber hereditary optic
- Bio-Techne and Narayana Nethralaya Collaborate On the Use of Ella for Ophthalmic Disorder Diagnostic Applicationshttps://modernod.com/news/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications/2479224/Bio-Techne announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-qualit